Citations

Clear

4610 citation(s) found for "Lu, Brian".

BHLHE40 programs mitochondrial regulation of resident CD8+ T cell fitness and functionality
ZHU, BIBO, Son, Youngmin , Hitosugi, Taro , Sun, Jie , Li, Chaofan , Wang, Zheng , Edelson, Brian T. , Rathmell, Jeffrey C. , Dong, Haidong

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 60.2-60.2

10.4049/jimmunol.202.supp.60.2 Get It

Abstract Tissue-resident memory CD8+ T cells (TRM) share characteristics and core residency gene programs with tumor-infiltrating lymphocytes (TILs). However, the transcriptional, metabolic and epigenetic regulation of TRM and TIL differentiation, maintenance and function are largely undefined. Furthermore, it is unknown whether metabolic and epigenetic manipulations can be employed to promote TRM/TIL functional programs for cancer immunotherapy. Here we report a critical mechanism programming the mitochondrial and epigenetic regulation of TRM/TIL functionality in situ. We find that mouse and human TRM/TIL express the transcription factor BHLHE40 and the BHLHE40-associated gene signature. Bhlhe40 is specifically required for TRM and TIL development and poly-functionality. Local PD-1 signaling inhibits TIL Bhlhe40 expression, and Bhlhe40 is critical for TIL reinvigoration following anti-PD therapy. Mechanistically, Bhlhe40 sustains TRM/TIL mitochondrial fitness for the promotion of a functional epigenetic state. Building on these findings, we also identify an epigenetic and metabolic regimen that promotes TRM/TIL gene signatures associated with tissue residency and poly-functionality through in vitro T cell screening. Strikingly, this regimen empowers the anti-tumor activity of CD8+ T cells and possesses therapeutic potential even at an advanced tumor stage in mouse models. Our results provide mechanistic insights on the local regulation of TRM and TIL function, and offer a viable strategy for developing novel immunotherapeutic means for cancer.
Lipoteichoic acid synergizes with ATP to activate dendritic cells for a pro-inflammatory TH17-polarizing phenotype (133.22)
Paustian, Christopher, Johnson, Terrence D., Czerniecki, Brian J. , Shu, Suyu, Cohen, Peter A. , Koski, Gary K.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: 1_Supplement | Pages: 133.22-133.22

10.4049/jimmunol.182.supp.133.22 Get It

Abstract Stimulation of dendritic cells (DCs) by exogenous danger signals such as single Toll-like receptor (TLR) ligands results in generalized DC activation. Recently, Napolitani and co-workers showed select TLR ligand pairings induced a more specialized DC activation program including enhanced IL-12 p70 secretion and the capacity to polarize CD4 T cells into IFN-γ-secreting Th1 cells. We therefore examined the effect of pairing an exogenous TLR2 ligand (lipoteichoic acid) with an endogenous danger signal, ATP, which is found in high extracellular concentrations in damaged tissues, malignant tumors, and possibly other pathophysiological settings. ATP added to LTA modified somewhat the expression of common DC activation markers, but primarily induced a distinct pattern of cytokines with greatly enhanced levels of both IL-23 and IL-1β, while TNF, IL-10 and IL-6 remained mostly unchanged. IL-12 was not produced. These DC induced a Th17 response when stimulating allogeneic T cells in a manner partially dependent on IL-1β. These studies show that pairing of endogenous and exogenous danger signals can induce a specialized DC activation program that may have important physiological implications.
Analysis of MHC Class II Genes in the Susceptibility to Lupus in New Zealand Mice
Rozzo, Stephen J., Vyse, Timothy J. , David, Chella S., Palmer, Ed, Izui, Shozo, Kotzin, Brian L.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 162 | Issue: 5 | Pages: 2623-2630

10.4049/jimmunol.162.5.2623 Get It

Abstract Hybrids of New Zealand Black (NZB) and New Zealand White (NZW) mice spontaneously develop a disease similar to human systemic lupus erythematosus. MHC and non-MHC genes contribute to disease susceptibility in this murine model. Multiple studies have shown that the NZW H2z locus is strongly associated with the development of lupus-like disease in these mice. The susceptibility gene(s) within H2z is not known, but different lines of evidence have pointed to class II MHC genes, either H2-E or H2-A (Ez or Az in NZW). Recent studies from our laboratory showed that Ez does not supplant H2z in the contribution to lupus-like disease. In the present work we generated C57BL/10 (B10) mice transgenic for Aaz and Abz genes (designated B10.Az mice) and used a (B10.Az × NZB)F1 × NZB backcross to assess the contributions of Az genes to disease. A subset of backcross mice produced high levels of IgG autoantibodies and developed severe nephritis. However, no autoimmune phenotype was linked to the Az transgenes. Surprisingly, in the same backcross mice, inheritance of H2b from the nonautoimmune B10 strain was strongly linked with both autoantibody production and nephritis. Taken together with our previous Ez studies, the present work calls into question the importance of class II MHC genes for lupus susceptibility in this model and provides new insight into the role of MHC in lupus-like autoimmunity.
Serologic Studies of I-E/I-C Gene Products in Haplotypes H-2b, H-2s, H-2q, and H-2f
David, Chella S., Neely, Brian C.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 121 | Issue: 4 | Pages: 1607-1607

10.4049/jimmunol.121.4.1607.d Get It

Abstract The I-E and I-C subregion products have been identified specifically in haplotypes H-2k and H-2d. Haplotypes H-2p and H-2r are assumed to express products of I-E/I-C subregion on the basis of cross-reactions with anti-I-Ek sera. Anti-I-Ek or I-Ed sera do not cross-react with haplotypes H-2s, H-2b, H-2q, and H-2f. Specific immunizations to produce anti-I-Eb and anti-I-Es alloantisera have been unsuccessful. We turned to xenoimmunization to serologically identify the gene products of this chromosomal segment in the above haplotypes. NP-40 detergent solubilized antigenic material mixed in Freund's complete adjuvant were immunized into rabbits. Two weeks later a booster was given and the rabbits bled one week later for antisera analyses. The rabbits were then boosted once a month and bled periodically. The rabbit antiserum reacted with all mouse strains. Absorptions with appropriate recombinants showed the presence of specific antibodies against the I region products. For example, rabbit anti-B10 serum after absorption with B10.A (3R) left residual activity against B10.A (18R), suggesting antigen(s) mapping between I-J and H-2D. The antiserum was further absorbed with B10.F (13R) to make it specific for I-E/IC subregions. Rabbit anti-B10.M sera, after absorption in ATFR.1 reacts with ATFR.5, suggesting activity in the K and I regions. Since absorption with platelets did not remove activity for spleen cells, presence of anti-If antibodies is suggested. Sequential immunoprecipitation analysis will be performed to screen for anti-I-E/I-C antibodies. Rabbit anti-B10.G and Rabbit anti-B10.S sera are currently being analyzed for I region activity.
Understanding neuronal gene expression changes induced by distal demyelination or inflammatory insult (BA6P.137)
Clarkson, Ben, Mirchia, Kanish , Kim, Hyo , LaFrance‐Corey, Reghann G., Howe, Charles W., Sauer, Brian, Howe, Charles

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 194 | Issue: 1_Supplement | Pages: 114.18-114.18

10.4049/jimmunol.194.supp.114.18 Get It

Abstract MR imaging suggests an anatomic correspondence between WM and GM lesions in progressing MS patients, suggesting an underlying neuronal-signaling or neurodegenerative element to the progressive disease state. While retrograde signals evolving from stressed axons that alter soma gene expression have been previously described in models of axonal transection or crush injury, those resulting from inflammation and demyelination are unknown. Using microfluidic chambers that segregate neuronal soma and axons, we have previously demonstrated increased axonal MHC I following treatment with IFNg, a cytokine prominent in demyelinating MS lesions. Furthermore, expression of antigen-loaded MHC I predisposed axons to injury by antigen-specific CD8+ T cells in vitro. Here we report that neurons also upregulate expression of MHC class Ib mRNAs in response to axonal stimulation with IFNg. Genes most highly upregulated following cytokine treatment included H2-M3, H2-Q5, H2-Q6, H2-Q7, H2-Q8, H2-T10 , and H2-T23. We further report the development of an in vivo model system for measuring axonal vulnerability to antigen-specific immune attack following demyelination using an AAV vector to induce neuron-specific expression of axonally-targeted neoantigen (ovalbumin) tagged with cleavable eGFP. We also present optimized methods using AAV vectors in mice for infecting retinal, motor cortex, and hippocampal neurons to induce target gene expression in axons projecting to optic nerve and corpus collosum.
Information and Data Visualization Needs among Direct Care Nurses in the Intensive Care Unit
Pinevich, Yuliya , Barwise, Amelia , Fathma, Sawsan, Diedrich, Daniel A. , Pickering, Brian W. , Lindroth, Heidi L., Diedrich, Daniel, Barwise, Amelia K , Lindroth, Heidi , Herasevich, Vitaly

Mayo Clinic

Applied Clinical Informatics | December 29, 2022 | Volume: 13 | Issue: 05 | Pages: 1207-1213

10.1055/s-0042-1758735 | PMID 36577501 Get It

Abstract Objectives Intensive care unit (ICU) direct care nurses spend 22% of their shift completing tasks within the electronic health record (EHR). Miscommunications and inefficiencies occur, particularly during patient hand-off, placing patient safety at risk. Redesigning how direct care nurses visualize and interact with patient information during hand-off is one opportunity to improve EHR use. A web-based survey was deployed to better understand the information and visualization needs at patient hand-off to inform redesign. Methods A multicenter anonymous web-based survey of direct care ICU nurses was conducted (9–12/2021). Semi-structured interviews with stakeholders informed survey development. The primary outcome was identifying primary EHR data needs at patient hand-off for inclusion in future EHR visualization and interface development. Secondary outcomes included current use of the EHR at patient hand-off, EHR satisfaction, and visualization preferences. Frequencies, means, and medians were calculated for each data item then ranked in descending order to generate proportional quarters using SAS v9.4. Results In total, 107 direct care ICU nurses completed the survey. The majority (46%, n = 49/107) use the EHR at patient hand-off to verify exchanged verbal information. Sixty-four percent (n = 68/107) indicated that current EHR visualization was insufficient. At the start of an ICU shift, primary EHR data needs included hemodynamics (mean 4.89 ± 0.37, 98%, n = 105), continuous IV medications (4.55 ± 0.73, 93%, n = 99), laboratory results (4.60 ± 0.56, 96%, n = 103), mechanical circulatory support devices (4.62 ± 0.72, 90%, n = 97), code status (4.40 ± 0.85, 59%, n = 108), and ventilation status (4.35 + 0.79, 51%, n = 108). Secondary outcomes included mean EHR satisfaction of 65 (0–100 scale, standard deviation = ± 21) and preferred future EHR user-interfaces to be organized by organ system (53%, n = 57/107) and visualized by tasks/schedule (61%, n = 65/107). Conclusion We identified information and visualization needs of direct care ICU nurses. The study findings could serve as a baseline toward redesigning an EHR interface.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Molloy, Mark P. , Morris, John C. , Berman, Sarah , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Day, Gregory S. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Mori, Hiroshi , Perrin, Richard J. , Levey, Allan I. , Masters, Colin L. , Fagan, Anne M. , Bateman, Randall J. , Martins, Ralph N. , Network, and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Levey, Allan I , Pedrini, Steve , Xiong, Chengjie , Benzinger, Tammie L.S. , Karch, Celeste M. , Cruchaga, Carlos , Lee, Jae‐Hong , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Teunissen, Charlotte E. , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | December 28, 2022 | Volume: 19 | Issue: 7 | Pages: 2790-2804

10.1002/alz.12879 | PMID 36576155 Get It

Abstract Background Glial fibrillary acidic protein (GFAP) is a promising candidate blood‐based biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its disease‐associated changes, its clinical correlates, and biofluid‐type dependency will influence its clinical utility. Methods We evaluated plasma, serum, and cerebrospinal fluid (CSF) GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Results Plasma GFAP elevations appear a decade before expected symptom onset, after amyloid beta (Aβ) accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished Aβ‐positive from Aβ‐negative ADAD participants and showed a stronger relationship with Aβ load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Conclusion Our findings support a role for plasma GFAP as a clinical biomarker of Aβ‐related astrocyte reactivity that is associated with cognitive decline and neurodegeneration. Highlights Plasma glial fibrillary acidic protein (GFAP) elevations appear a decade before expected symptom onset in autosomal dominant Alzheimer's disease (ADAD). Plasma GFAP was associated to amyloid positivity in asymptomatic ADAD. Plasma GFAP increased with clinical severity and predicted disease progression. Plasma and serum GFAP carried similar information in ADAD, while cerebrospinal fluid GFAP did not.
Development and validation of a recursive partitioning analysis–based pretreatment decision‐making tool identifying ideal candidates for spine stereotactic body radiation therapy
Kowalchuk, Roman O. , Mullikin, Trey C. , Florez, Marcus A. , De, Brian , Spears, Grant M. , Rose, Peter S. , Kim, Dong Kun , Costello, Brian A. , Marion, Joseph , Johnson‐Tesch, Benjamin A., Gao, Robert W. , Shiraishi, Satomi , Lucido, J. John , Olivier, Kenneth R. , Owen, Dawn , Stish, Bradley J. , Waddle, Mark R. , Brown, Paul D. , Ghia, Amol J. , Merrell, Kenneth W. , Marion, Joseph T , Johnson-Tesch, Benjamin A, Lucido, John J , Trifiletti, Daniel M , Waddle, Mark R , Brown, Paul D , Merrell, Kenneth W , Kowalchuk, Roman O. , Shiraishi, Satomi , Siontis, Brittany L. , Morris, Jonathan M. , Trifiletti, Daniel M. , Laack, Nadia N. , Park, Sean S.

Mayo Clinic

Cancer | December 26, 2022 | Volume: 129 | Issue: 6 | Pages: 956-965

10.1002/cncr.34626 | PMID 36571507 Get It

AbstractBackgroundThis study was aimed at developing and validating a decision‐making tool predictive of overall survival (OS) for patients receiving stereotactic body radiation therapy (SBRT) for spinal metastases.MethodsThree hundred sixty‐one patients at one institution were used for the training set, and 182 at a second institution were used for external validation. Treatments most commonly involved one or three fractions of spine SBRT. Exclusion criteria included proton therapy and benign histologies.ResultsThe final model consisted of the following variables and scores: Spinal Instability Neoplastic Score (SINS) ≥ 6 (1), time from primary diagnosis < 21 months (1), Eastern Cooperative Oncology Group (ECOG) performance status = 1 (1) or ECOG performance status > 1 (2), and >1 organ system involved (1). Each variable was an independent predictor of OS (p < .001), and each 1‐point increase in the score was associated with a hazard ratio of 2.01 (95% confidence interval [CI], 1.79–2.25; p < .0001). The concordance value was 0.75 (95% CI, 0.71–0.78). The scores were discretized into three groups—favorable (score = 0–1), intermediate (score = 2), and poor survival (score = 3–5)—with 2‐year OS rates of 84% (95% CI, 79%–90%), 46% (95% CI, 36%–59%), and 21% (95% CI, 14%–32%), respectively (p < .0001 for each). In the external validation set (182 patients), the score was also predictive of OS (p < .0001). Increasing SINS<zaq;6> was predictive of decreased OS as a continuous variable (p < .0001).ConclusionsThis novel score is proposed as a decision‐making tool to help to optimize patient selection for spine SBRT. SINS may be an independent predictor of OS.
A comparison of treating physician versus independent core lab assessments of post–aneurysm treatment imaging outcomes: an analysis of prospectively collected data from a randomized trial
Patra, Devi Prasad, Syal, Arjun , Rahme, Rudy J. , Abi-Aad, Karl R., Turcotte, Evelyn L. , Jones, Breck A., Meyer, Jenna , Hudson, Miles , Chong, Brian W. , Dabus, Guilherme , James, Robert F. , Krishna, Chandan , Patra, Devi P. , Singh, Rohin , Dabus, Guilherme C. , Bendok, Bernard R.

Mayo Clinic

Journal of Neurosurgery | December 23, 2022 | Volume: 139 | Issue: 1 | Pages: 85-93

10.3171/2022.10.jns22841 | PMID 36681980 Get It

OBJECTIVE Aneurysm occlusion has been used as surrogate marker of aneurysm treatment efficacy. Aneurysm occlusion scales are used to evaluate the outcome of endovascular aneurysm treatment and to monitor recurrence. These scales, however, require subjective interpretation of imaging data, which can reduce the utility and reliability of these scales and the validity of clinical studies regarding aneurysm occlusion rates. Use of a core lab with independent blinded reviewers has been implemented to enhance the validity of occlusion rate assessments in clinical trials. The degree of agreement between core labs and treating physicians has not been well studied with prospectively collected data. METHODS In this study, the authors analyzed data from the Hydrogel Endovascular Aneurysm Treatment (HEAT) trial to assess the interrater agreement between the treating physician and the blinded core lab. The HEAT trial included 600 patients across 46 sites with intracranial aneurysms treated with coiling. The treating site and the core lab independently reviewed immediate postoperative and follow-up imaging (3–12 and 18–24 months, respectively) using the Raymond-Roy occlusion classification (RROC) scale, Meyer scale, and recanalization survey. A post hoc analysis was performed to calculate interrater reliability using Cohen’s kappa. Further analysis was performed to assess whether degree of agreement varied on the basis of various factors, including scale used, timing of imaging, size of the aneurysm, imaging modality, location of the aneurysm, dome-to-neck ratio, and rupture status. RESULTS Minimal interrater agreement was noted between the core lab reviewers and the treating physicians for assessing aneurysm occlusion using the RROC grading scale (k = 0.39, 95% CI 0.38–0.40) and Meyer scale (k = 0.23, 95% CI 0.14–0.38). The degree of agreement between groups was slightly better but still weak for assessing recanalization (k = 0.45, 95% CI 0.38–0.52). Factors that significantly improved degree of agreement were scales with fewer variables, greater time to follow-up, imaging modality (digital subtraction angiography), and wide-neck aneurysms. CONCLUSIONS Assessment of aneurysm treatment outcome with commonly used aneurysm occlusion scales suffers from risk of poor interrater agreement. This supports the use of independent core labs for validation of outcome data to minimize reporting bias. Use of outcome tools with fewer point categories is likely to provide better interrater reliability. Therefore, the outcome assessment tools are ideal for clinical outcome assessment provided that they are sensitive enough to detect a clinically significant change.
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
Saporta, A. , Barry, John J., Omotola, Hope, O’Brien, Terence J. , Nadkarni, Siddhartha, Winawer, Melodie R., French, Jacqueline A. , Abou‐Khalil, Bassel , Alldredge, Brian K., Bebin, Martina , Cascino, Gregory D. , Cook, Mark , Detyniecki, Kamil , Dlugos, Dennis , Faught, Edward, Ficker, David M. , Fields, Madeline , Glynn, Simon, Halford, Jonathan J. , Haut, Sheryl R., Hegde, Manu , Kälviäinen, Reetta , Knowlton, Robert C. , Krishnamurthy, Kaarkuzhali Babu , Kwan, Patrick , Lowenstein, Daniel H. , Marcuse, Lara , Meador, Kimford J. , Mintzer, Scott , Pardoe, Heath , Penovich, Patricia , Singh, Rani K. , Szabó, C. Ákos , Szaflarski, Jerzy P. , Burneo, Jorge G. , Project, and the Human Epilepsy, French, Jacqueline A. , Kanner, Andres M, Saporta, Anita S, Kim, Dong H, Altalib, Hamada , Jetté, Nathalie , O'Brien, Terence J, Sperling, Michael, Abou-Khalil, Bassel, Alldredge, Brian, Cook, Mark J , Ficker, David, Gidal, Barry, Gelfand, Michael , Haut, Sheryl, Holmes, Manisha G, Kang, Joon, Klein, Pavel , Krishnamurthy, Kaarkuzhali, Kuzniecky, Ruben , Pardoe, Heath R , Park, Kristen , Szabo, Charles A, Lin Thio, K Liu, Halford, Jonathan J , French, Jacqueline , Meador, Kimford J , Burneo, Jorge G , Kanner, Andres Miguel , Kim, Dong , Sperling, Michael R. , Cole, Andrew J. , Devinsky, Orrin , Gidal, Barry E. , Holmes, Manisha , Kang, Joon Won , Somerville, Ernest , Thio, Liu Lin , Trinka, Eugen , Project, and the Human Epilepsy

Mayo Clinic

Neurology | December 20, 2022 | Volume: 100 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000201671 | PMID 36539302 Get It